Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Stopped early

Conditions studied: Keratoconus, Ectasia, Degeneration

In brief

To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication

Key facts

Study ID

NCT01024322

Run by

Cxlusa

People needed

1189

Starts

2009-10-01

Expected to finish

2017-02-03

Last updated by the study team

2018-10-11

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 8 years of age or older
• Diagnosis of keratoconus, post-LASIK ectasia, or pellucid marginal degeneration or forme fruste pellucid marginal degeneration.
• Diagnosis of FFKC
• History of Radial Keratotomy with fluctuating vision.
• Terrien's Marginal Degeneration
• Ability to provide written informed consent
• Likely to complete all study visits
• Minimum corneal thickness of at least 300 250 microns measured by ultrasound or Pentacam for all indications other than Terriens. For Terriens, the minimal corneal thickness should be consistent with the surgeon's best surgical judgment.

You may not qualify if…

• Severe corneal scarring that markedly affects vision
• Contraindications to any study medications or their components
• Pregnancy or breast feeding
• Active Herpes Corneal Disease

Where it is running

• The Center for Excellence in Eye Care — Miami, Florida, United States
• TLC Laser Eye Center — Rockville, Maryland, United States
• TLC Laser Eye Center — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.